Data investigation

Retatrutide Cost (2026): What Will Determine Pricing Once FDA-Approved

Retatrutide is not FDA-approved and Lilly has not announced a list price. This article walks the six mechanisms that will set the eventual price: WAC, PBM rebate stack, commercial coverage, Lilly direct-pay self-pay portal, HSA/FSA eligibility, and Medicare/Medicaid timing.

By Eli Marsden · Founding Editor
Editorially reviewed & fact-checked against primary sources · How we verify contentLast reviewed
11 min read·12 citations

Retatrutide (Eli Lilly investigational code LY3437943, GIP/GLP-1/glucagon triple agonist) is not FDA-approved as of October 2026 (the FDA's drug approval database has no application record for retatrutide). Lilly has not yet submitted its application to the FDA, has not announced a brand name, and has not published any list price. There is no “retatrutide cost” figure to quote because retatrutide is not yet a commercial product. The two pivotal Phase 3 obesity trials are now published: in TRIUMPH-1 (NEJM 2026), adults with obesity and no diabetes lost 23.7% (9 mg) and 25.0% (12 mg) of body weight at 80 weeks versus 3.9% on placebo,[8] and in TRIUMPH-2 (Lancet 2026), adults with obesity and type 2 diabetes lost 16.8% and 18.8% versus 5.1%.[9] Lilly's August 2026 earnings release says it plans to submit a Biologics License Application (BLA) to the FDA in the first quarter of 2027.[10] What we can do — and what this article does — is walk through every mechanism that has determined the price of every other GLP-1 brand at launch, so that when Lilly does publish a Wholesale Acquisition Cost (WAC) and a direct-pay self-pay portal, you will already know which levers move the number you pay.

Why this article does not quote dollar amounts

Every dollar figure for an unapproved drug is a speculation. Lilly has not committed to a launch price for retatrutide. PBMs have not built formulary tiers around it. CMS has not begun the National Coverage Determination process. Quoting a number today would require us to update this page the day Lilly issues a press release — and every secondary source that cited the old number would become wrong. Instead, we describe the six mechanisms that will set the number, anchored to how Wegovy, Zepbound, and Foundayo were actually priced at their launches. For broader context see our retatrutide approval & access timeline and the GLP-1 pricing index for live brand-by-brand pricing.

The honest short answer

Retatrutide is unapproved. There is no list price, no manufacturer self-pay portal, no PBM rebate stack, and no insurance formulary tier. Any retailer or telehealth listing offering “retatrutide” today is selling a compounded version that sits in a contested regulatory gray area — retatrutide is not on the FDA Drug Shortage List, has no USP/NF monograph, and is not on either the 503A or 503B bulks list, so the standard FDA compounding pathways do not authorize it.[5] FDA has issued Warning Letters to compounders distributing retatrutide — a September 9, 2025 enforcement sweep of more than 40 letters to telehealth-affiliated compounders (including GLP-1 Solution, ASN-LABS, GenLabMeds, Amazing Meds, and MedClub by Dr. Jenn) each cite the recipient's “compounded retatrutide drug products” as failing FDCA §§503A and 503B. Earlier December 10, 2024 letters targeted research-peptide resellers Xcel Research LLC and Swisschems for unapproved retatrutide / LY-3437943 sales.

Once Lilly submits its BLA (planned for the first quarter of 2027[10]) and the FDA approves it, pricing will be determined by six mechanisms in sequence: (1) the WAC Lilly publishes at launch, (2) PBM formulary placement and the rebate stack, (3) commercial-insurance coverage and prior-authorization criteria, (4) a Lilly-operated direct-pay self-pay portal analogous to LillyDirect for Zepbound, (5) HSA/FSA eligibility once an FDA-approved indication exists, and (6) Medicare Part D and state-Medicaid formulary timing, which typically lag commercial coverage by 6-18 months.

Why we do not quote current “retatrutide $X” figures

Three reasons. First, retatrutide has no FDA-approved indication, so any product labeled “retatrutide” in commerce today is a compounded preparation, and compounded pricing varies by pharmacy, dose, vial size, and whether the pharmacy is a 503A patient-specific compounder or a 503B outsourcing facility. None of those configurations represent the price retatrutide will carry as a Lilly brand-name product.

Second, the legality of compounded retatrutide is unsettled. The FDA framework reserves 503A patient-specific compounding for active ingredients that either appear on the USP/NF compendium, are components of an FDA-approved drug, or appear on the FDA 503A bulks list. Retatrutide satisfies none of those criteria.[5] Listing a price for an unauthorized product would imply normalization.

Third, brand-name GLP-1 launch prices have moved dramatically year over year. The first wave of Wegovy and Zepbound list prices (2021-2023) was reset by Novo Nordisk and Lilly direct-pay portals in 2024-2025, which were reset again by oral-GLP-1 entrants in 2026.[4] Any number we baked into the article body today would be stale within a fiscal quarter of retatrutide's actual approval.

What determines GLP-1 brand pricing once approved

Six mechanisms set the number you actually pay for a brand-name GLP-1 in the United States. They apply to every approved GLP-1 today (Wegovy, Zepbound, Foundayo, Saxenda, Ozempic, Mounjaro, Rybelsus) and will apply to retatrutide once Lilly launches it.

1. Wholesale Acquisition Cost (WAC)

The WAC is the manufacturer's published list price to wholesalers, before any rebates, discounts, or coupons. It is the number reported in databases like First Databank and Medi-Span and the number that pharmacies start from when calculating cash-pay or insurance-billed prices. Lilly will set the retatrutide WAC at launch. Historically the new-entrant WAC for a higher-efficacy GLP-1 has come in at or above the comparator-class WAC (Zepbound launched at roughly the Wegovy WAC band), but Lilly's recent strategy with Foundayo has been to anchor the oral pill at a substantially lower self-pay tier — a pricing tactic that depends on Lilly's commercial judgment about whether the broader market rewards aggressive entry pricing.

2. PBM formulary placement and the rebate stack

Pharmacy Benefit Managers (CVS Caremark, Express Scripts, OptumRx) negotiate rebates with manufacturers and decide which GLP-1s sit on the “preferred” tier of a plan's formulary. The rebate is a percentage off the WAC that the manufacturer pays the PBM in exchange for preferred placement; the net price the plan actually pays is the WAC minus the rebate. PBM placement determines your copay, your prior-authorization burden, and whether the drug appears on the formulary at all. The CVS Caremark 2025 formulary swap that removed Zepbound from most commercial plans in favor of Wegovy, and Caremark's decision to add Zepbound back as an additional preferred option on October 1, 2026,[12] is the case study every patient should understand before assuming retatrutide will be covered: preferred status can be taken away and given back as rebate deals change.

3. Commercial insurance coverage and prior authorization

Once a GLP-1 is on the formulary, the plan typically attaches prior-authorization (PA) criteria: BMI threshold, comorbidity requirement, prior-trial-and-failure requirement (often a 3-6 month documented diet-and-exercise attempt), and reauthorization gates at 6-12 months contingent on documented weight loss. Retatrutide's PA criteria will not exist until plans build them — typically 3-9 months after FDA approval — and will likely mirror the existing weight-management GLP-1 PA template (Wegovy, Zepbound, Saxenda).

4. Manufacturer direct-pay portals

Lilly operates LillyDirect for Zepbound vials and the Self Pay Pharmacy for Foundayo. Novo Nordisk operates NovoCare Pharmacy for Wegovy. These portals sell directly to patients at a manufacturer-set self-pay price, bypassing the PBM rebate stack entirely. Self-pay pricing is typically substantially below the WAC. Lilly has signaled commitment to a “patient-centric” pricing approach for retatrutide once approved — which in Lilly's recent track record has meant a tiered direct-pay portal with lower self-pay prices at lower doses. The presence of such a portal at retatrutide launch is highly likely but not committed. Until then, Zepbound is the Lilly drug you can actually fill, and our retatrutide vs Zepbound breakdown covers how the trial results and current access differ.

5. HSA / FSA eligibility

Prescription medications for an FDA-approved indication are HSA- and FSA-eligible under IRS Publication 502. An unapproved drug is not. Once retatrutide receives an FDA-approved indication for chronic weight management (the expected indication based on the TRIUMPH program), HSA and FSA dollars become available to offset out-of-pocket cost — which can move the effective price by a third or more for patients in the 22-32% marginal-tax brackets.

6. Medicare Part D and state Medicaid timing

Medicare Part D coverage of weight-management GLP-1s remains restricted. Historically, Part D has excluded drugs “used for anorexia, weight loss, or weight gain” per the statute — Wegovy gained Part D coverage only after the SELECT trial established a cardiovascular-disease indication.[6] Retatrutide's Part D coverage will depend on whether TRIUMPH-3 (the cardiovascular outcomes trial, primary completion ~2029) establishes a parallel non-weight indication. State Medicaid coverage varies by state and typically lags commercial coverage by 6-18 months — see our GLP-1 insurance coverage audit for the state-by-state pattern.

How Wegovy / Zepbound / Foundayo were priced at launch

The historical pattern across the three most recent weight-management GLP-1 launches is consistent enough to be predictive:

  • Initial WAC announced concurrent with FDA approval, set in the band of the comparator class (typically not aggressively below).
  • PBM rebate negotiations occur over the following 3-9 months, with formulary updates dropping at standard 1st-of-the-month effective dates. During this window patients typically pay full WAC.
  • Manufacturer copay savings cards launch concurrent with WAC for commercially insured patients, reducing copay to a manufacturer-funded floor for a capped number of fills.
  • A direct-pay self-pay portal launches 3-12 months post-approval at a manufacturer-set self-pay price meaningfully below WAC, bypassing insurance.
  • Dose-tiered self-pay pricing emerges subsequently, with lower doses priced lower than higher doses — the pattern Lilly established with LillyDirect Zepbound vials.
  • Medicare and state Medicaid coverage lag commercial by 6-18 months and remain restricted even after coverage exists. Coverage timing depends heavily on cardiovascular-outcomes trial readouts that establish non-weight indications.

Retatrutide will almost certainly follow the same sequence, with the variable being how aggressively Lilly prices the direct-pay portal relative to PBM-channel pricing. Lilly's 2026 Foundayo launch was unusually aggressive on the self-pay portal — a strategy that rewarded Lilly with market-share capture at the expense of PBM-channel margin. Whether Lilly repeats that strategy for retatrutide will be a function of competitive pressure from Novo Nordisk's pipeline (CagriSema, semaglutide 4.5 mg) and Amgen's MariTide.

Lilly's pricing track record

Lilly has launched three high-profile metabolic-disease drugs in the past four years that inform what we can expect from a retatrutide launch:

  • Mounjaro (tirzepatide, T2D indication, 2022 approval) — launched at a WAC roughly in line with the Ozempic comparator band. No initial direct-pay portal; PBM-channel pricing dominated. Manufacturer copay savings card was the primary patient-facing discount vehicle.
  • Zepbound (tirzepatide, weight-management indication, 2023 approval) — launched at a WAC band similar to Wegovy. LillyDirect direct-pay self-pay portal launched in 2024 selling vials at meaningfully lower self-pay prices than the prefilled pen. Dose-tiered self-pay pricing was the structural innovation: lower doses priced lower than higher doses, which moved patients toward staying at lower maintenance doses.
  • Foundayo (orforglipron, oral weight-management GLP-1, 2026 approval) — launched with the aggressive Self Pay Pharmacy self-pay tier from day one (no waiting period for the direct-pay portal) and simultaneous Amazon Pharmacy listing. The Foundayo launch was the most patient-pricing-aggressive of the three Lilly metabolic launches.

The trajectory is toward earlier and more aggressive direct-pay self-pay portals. If the pattern holds, retatrutide will launch with a same-day direct-pay portal and dose-tiered self-pay pricing.

Compounded retatrutide and the pre-approval question

Some telehealth providers and compounding pharmacies currently list “compounded retatrutide” in their menus. The regulatory framework for those listings is contested.

Compounding under FDA 503A requires that the active ingredient meet one of three conditions: appear on the USP/NF compendium, be a component of an FDA-approved drug, or appear on the FDA 503A bulks list. Retatrutide does not satisfy any of the three. 503B outsourcing facilities require either inclusion on the 503B bulks list or inclusion on the FDA Drug Shortage List. Retatrutide appears on neither.[5] FDA has issued Warning Letters to multiple compounders distributing retatrutide in 2024-2025.

For the practical patient-facing question of whether compounded retatrutide is “safe” or “legitimate” today, the answer requires separating three things: the pharmaceutical-grade peptide chemistry (which can be high quality from a properly equipped 503A pharmacy), the regulatory authorization (which is absent), and the clinical oversight (which depends on whether the prescriber is licensed and is following a documented protocol). The absence of FDA authorization means there is no FDA-supervised manufacturing audit, no FDA-supervised labeling, and no post-market adverse-event reporting infrastructure. For deeper detail see our retatrutide approval & access timeline article, which covers these boundaries explicitly.

Insurance coverage timeline

Once FDA approves retatrutide, the typical commercial insurance coverage pattern unfolds over 6-12 months:

  • Month 0-3 post-approval: WAC is published; manufacturer copay savings card is available for commercially insured patients. Most commercial plans have not yet built PA criteria; patients pay full WAC or use the savings card to a manufacturer-funded floor.
  • Month 3-9 post-approval: PBMs negotiate rebate contracts with Lilly and update formularies. New GLP-1 typically appears as a non-preferred or preferred option depending on the rebate Lilly offers vs the Wegovy / Zepbound rebate already in place. Prior authorization criteria are published.
  • Month 9-18 post-approval: Most large commercial plans have built PA criteria and step-therapy requirements. Patients can access retatrutide through insurance subject to PA. Direct-pay portal pricing stabilizes.
  • Year 2+: Medicare Part D and state Medicaid coverage decisions begin to land, contingent on whether Lilly secures a non-weight indication via TRIUMPH-3 cardiovascular outcomes or other label expansion. Without such an indication, Part D and Medicaid coverage will remain restricted by the statutory weight-loss-drug exclusion.[6]

When to expect pricing transparency

A list price normally arrives with FDA approval, so the timing depends on the review clock. Lilly plans to submit a Biologics License Application in the first quarter of 2027.[10] FDA's performance goal for an original BLA is to act within 10 months of the 60-day filing date under standard review, or within 6 months of that date under priority review.[11] On those goals, a Q1 2027 submission points to an FDA decision around late 2027 (priority review) or early 2028 (standard review). TRIUMPH-1 (NCT05929066) and TRIUMPH-2 (NCT05929079) are complete and published,[2][7][8][9] but the submission has not happened yet, so the pricing timeline remains a projection, not a confirmed schedule.

Lilly typically announces WAC, manufacturer copay savings card terms, and direct-pay portal availability concurrent with the FDA approval press release. So the day the FDA approves retatrutide is the day pricing transparency begins. Until that date, no published number is authoritative.

How patients can prepare financially before approval

Specific preparation steps for patients planning to ask about retatrutide once it lands:

  • Verify your insurance covers the GLP-1 class. If your plan does not cover Wegovy, Zepbound, or Foundayo today, the chance it will cover retatrutide at launch is low. Our GLP-1 insurance coverage audit walks through how to check.
  • Document a clinical baseline. BMI, comorbidities (T2D, hypertension, dyslipidemia, sleep apnea), and any prior weight-loss-drug history. Prior-authorization criteria for retatrutide will almost certainly require some or all of these.
  • Establish a relationship with a prescriber comfortable with GLP-1 therapy. The provider who currently prescribes your Wegovy or Zepbound is the one most likely to be willing to switch you to retatrutide once it's available.
  • Build an HSA balance if eligible. HSA-eligible high-deductible plans paired with HSA contributions create a tax-advantaged dollar pool that will be available to pay for retatrutide out-of-pocket once an FDA-approved indication exists.
  • Read the comparator data. The closest FDA-approved mechanism to retatrutide is tirzepatide (Zepbound for weight management). See our retatrutide triple-agonist evidence deep-dive and the Foundayo vs Wegovy head-to-head evidence for the framework.
  • Do not commit cash to gray-market compounded retatrutide before FDA approval. The regulatory status is unsettled, the pricing is not predictive of eventual brand pricing, and patient-safety oversight is absent.

Bottom line

Retatrutide is not approved by the FDA. There is no list price to quote. Once Lilly submits its Biologics License Application (planned for the first quarter of 2027) and the FDA approves the drug (plausibly late 2027 at the earliest), the price you pay will be set by six mechanisms in sequence: WAC, PBM rebate, commercial-insurance coverage, Lilly's direct-pay portal, HSA/FSA eligibility, and Medicare/Medicaid timing. Lilly's recent pricing track record — Mounjaro, Zepbound, Foundayo — trends toward earlier and more aggressive direct-pay self-pay portals, which is the single most important variable for cash-pay patients to watch. Do not commit cash to gray-market compounded retatrutide while waiting; FDA enforcement posture is active and the regulatory status is unsettled. Until Lilly publishes a WAC, no “retatrutide $X” number is authoritative.

Further reading

Key terms, explained

New to GLP-1s? Tap any term for a quick, plain-English definition.

Frequently Asked Questions

Retatrutide is not FDA-approved as of October 2026 (verified directly against openFDA's drugsfda database, which has no record for retatrutide) and Lilly has not announced a list price. There is no authoritative 'retatrutide cost' figure. TRIUMPH-1 and TRIUMPH-2, the two pivotal obesity trials, are complete and published (NEJM and Lancet, 2026). Lilly's August 2026 earnings release says it plans to submit a Biologics License Application to the FDA in the first quarter of 2027. Once the FDA approves the drug, pricing will be set by six mechanisms: the Wholesale Acquisition Cost Lilly publishes, PBM rebate negotiations and formulary placement, commercial-insurance coverage and prior-authorization criteria, Lilly's direct-pay self-pay portal, HSA/FSA eligibility, and Medicare/Medicaid coverage timing.
Because retatrutide is not yet a commercial product. Quoting a number today would require the article to be updated the day Lilly issues its approval press release, and every secondary source citing the old number would become wrong. Instead we describe the six mechanisms that will set the eventual price, anchored to how Wegovy, Zepbound, and Foundayo were priced at their launches.
Some telehealth providers and compounding pharmacies list compounded retatrutide today, but the regulatory framework for those listings is contested. Retatrutide is not on the FDA Drug Shortage List, has no USP/NF monograph, and is not on the 503A or 503B bulks lists — none of the standard FDA compounding pathways authorize it. FDA's GLP-1 safety page states verbatim that 'Retatrutide and cagrilintide cannot be used in compounding under federal law,' and on September 9, 2025 FDA issued Warning Letters to GLP-1 Solution, ASN-LABS, GenLabMeds, Amazing Meds, and MedClub by Dr. Jenn citing their compounded retatrutide products as failing FDCA §§503A and 503B. Compounded pricing varies by pharmacy but is not predictive of eventual brand pricing once Lilly launches the FDA-approved version.
Coverage will follow the typical commercial-insurance timeline: 3-9 months after FDA approval for PBM rebate negotiations and formulary placement, then 6-18 months for prior-authorization criteria to stabilize. Plans that already cover Wegovy or Zepbound are most likely to add retatrutide. Plans that exclude the weight-management GLP-1 class entirely (some employer-sponsored plans do) are unlikely to add it. Medicare Part D coverage is restricted by the statutory weight-loss-drug exclusion unless Lilly secures a non-weight indication via TRIUMPH-3 cardiovascular outcomes or a similar trial.
We do not know. The historical pattern is that new higher-efficacy GLP-1 entrants launch at or above the existing class WAC. However, Lilly's 2026 Foundayo launch broke that pattern with an aggressive direct-pay self-pay portal from day one. If Lilly applies the same strategy to retatrutide, the direct-pay self-pay price could be competitive with current Wegovy and Zepbound self-pay tiers. The PBM-channel insurance pricing is a different question and depends on rebate negotiations that have not occurred.
Concurrent with the FDA approval press release. Lilly typically announces WAC, manufacturer copay savings card terms, and direct-pay portal availability the same day the FDA approval letter is issued. Lilly plans to submit its Biologics License Application in the first quarter of 2027. Under FDA's review goals (6 months after the 60-day filing date for priority review, 10 months for standard review), that points to an FDA decision around late 2027 at the earliest, or early 2028 under standard review.
Six steps: (1) verify your insurance covers the GLP-1 class today by checking your formulary for Wegovy, Zepbound, or Foundayo; (2) document your clinical baseline (BMI, comorbidities, prior weight-loss-drug history) for future prior authorizations; (3) establish a prescriber relationship; (4) build an HSA balance if you are on an HSA-eligible high-deductible plan; (5) read the comparator evidence on tirzepatide (Zepbound) and Foundayo so you can evaluate retatrutide on day one; (6) do not commit cash to gray-market compounded retatrutide while waiting.
Not yet — prescription medications must be for an FDA-approved indication to qualify under IRS Publication 502. Once retatrutide receives an FDA-approved indication for chronic weight management (the expected outcome based on the TRIUMPH program), HSA and FSA dollars will be eligible to offset out-of-pocket cost.
There is no legitimate cash-pay price, because retatrutide is investigational — it is not FDA-approved and cannot be legally sold as a finished drug in the United States, so no regulated retail or self-pay price exists yet. Any 'price without insurance' advertised today comes from gray-market 'research chemical' vendors, which are unregulated, are not verified for identity, purity, or sterility, and are not legal or safe for human use — we do not quote or endorse those prices. If and when the FDA approves retatrutide, self-pay pricing would likely resemble other branded GLP-1 drugs, which carry list prices around $1,000+ per month before insurance or manufacturer savings. Until then, the appropriate step is to talk with a licensed clinician about FDA-approved options such as semaglutide (Wegovy) or tirzepatide (Zepbound).
Retatrutide is investigational, so its potential benefits are described from clinical trials rather than from approved use. It is a triple GIP/GLP-1/glucagon receptor agonist, and in a Phase 2 trial it produced the largest weight loss — roughly 24% of body weight — of any GLP-1-class drug studied so far. The glucagon component may increase energy expenditure and fat oxidation in addition to the appetite-lowering effect it shares with other GLP-1 drugs. The important caveats: the Phase 3 TRIUMPH program is not complete, the full safety profile is still being characterized, and retatrutide is not yet FDA-approved or legally available as a finished drug. Anyone interested should discuss FDA-approved options with a licensed clinician rather than sourcing retatrutide from gray-market vendors.
In cross-trial comparisons — not head-to-head studies — retatrutide produced numerically more weight loss (around 24% of body weight in Phase 2) than semaglutide (roughly 15%) or tirzepatide (roughly 21%). The larger figure is generally attributed to its added glucagon-receptor activity on top of GIP and GLP-1. Two caveats matter: cross-trial numbers are not a substitute for a direct comparison, and retatrutide is still investigational, whereas semaglutide (Wegovy) and tirzepatide (Zepbound) remain the only FDA-approved options in this class for weight management. A licensed clinician can help you weigh the approved treatments; retatrutide is not yet a legal or verified option to purchase.

References

  1. 1.Jastreboff AM, Kaplan LM, Frias JP, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023. PMID: 37366315.
  2. 2.Eli Lilly and Company. TRIUMPH-1 (A Study of Retatrutide in Adult Participants Who Have Obesity or Are Overweight) — ClinicalTrials.gov. ClinicalTrials.gov. 2026. https://clinicaltrials.gov/study/NCT05929066
  3. 3.Eli Lilly and Company. TRIUMPH-4 (Retatrutide in Adults With Obesity and Knee Osteoarthritis) — ClinicalTrials.gov. ClinicalTrials.gov. 2026. https://clinicaltrials.gov/study/NCT05931367
  4. 4.Eli Lilly and Company. Lilly's triple agonist, retatrutide, delivered weight loss of up to an average of 71.2 lbs along with substantial relief from osteoarthritis pain in first successful Phase 3 trial — Press Release. Eli Lilly Investor Relations. 2025. https://www.prnewswire.com/news-releases/lillys-triple-agonist-retatrutide-delivered-weight-loss-of-up-to-an-average-of-71-2-lbs-along-with-substantial-relief-from-osteoarthritis-pain-in-first-successful-phase-3-trial-302638804.html
  5. 5.U.S. Food & Drug Administration. Compounding and the FDA: Questions and Answers — 503A vs 503B framework. FDA.gov. 2025. https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers
  6. 6.Centers for Medicare & Medicaid Services. Medicare Part D Drug Coverage — Formulary additions and the National Coverage Determination process. CMS.gov. 2025. https://www.cms.gov/medicare/coverage
  7. 7.Eli Lilly and Company. TRIUMPH-2 (A Study of Retatrutide in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight) — ClinicalTrials.gov. Status as of August 2026: overallStatus COMPLETED, completion date June 16, 2026 (actual); results not yet posted to the registry. ClinicalTrials.gov. 2026. https://clinicaltrials.gov/study/NCT05929079
  8. 8.Jastreboff AM, Kaplan LM, Davies MJ, Wilding JPH, et al.; TRIUMPH-1 Investigators. Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity. N Engl J Med. 2026. PMID: 42814954.
  9. 9.Bellido V, le Roux CW, Ekinci EI, Bjornstad P, Frias JP, Giblin K, et al. Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial. Lancet. 2026. PMID: 42810372.
  10. 10.Eli Lilly and Company. Lilly reports second-quarter 2026 financial results (Form 8-K exhibit). U.S. Securities and Exchange Commission. 2026. https://www.sec.gov/Archives/edgar/data/0000059478/000005947826000077/q226lillysalesandearningsp.htm
  11. 11.U.S. Food and Drug Administration. PDUFA Reauthorization Performance Goals and Procedures, Fiscal Years 2023 Through 2027 (PDUFA VII commitment letter). FDA.gov. 2022. https://www.fda.gov/media/151712/download
  12. 12.CVS Health (CVS Caremark). CVS Caremark delivers affordability and access to GLP-1 weight management medications with expanded coverage options (May 28, 2026) — Zepbound added back to commercial formularies as an additional preferred option October 1, 2026; new-to-market block on Foundayo (orforglipron) removed effective June 1, 2026, where approved for coverage by plans. cvshealth.com. 2026. https://www.cvshealth.com/news/company-news/cvs-caremark-delivers-affordability-and-access-to-glp-1-weight-management-medications-with-expanded-coverage-options.html

Zepbound vs Wegovy Cost (2026): Self-Pay, Insurance Copay, Caremark Formulary & Total-Cost Comparison

Zepbound costs $299-$449/month in LillyDirect vials and Wegovy $349/month at NovoCare; SURMOUNT-5 data give the cost per pound lost. Plus $25 copay cards, Sam's Club pricing and the CVS Caremark formulary swap.

9 min read

Sesame vs LillyDirect for Cash-Pay Zepbound: Which Is Cheapest?

Both Sesame Care and LillyDirect's self-pay purchase offer offer cash-pay Zepbound, but the price ladders differ. We map Sesame's $30-$99 visit fees vs LillyDirect's $299/$399/$449 vial pricing — and the trade-offs around shipping, telehealth visits, and refill cadence.

11 min read

Retatrutide Approval & Access Timeline: TRIUMPH Results, 2027 FDA Filing, No Compounding

Retatrutide is not FDA-approved. Lilly plans to file in the first quarter of 2027, so it will not be prescribable in 2026. TRIUMPH-1 showed up to 25.0% weight loss at 80 weeks, and it cannot legally be compounded under 503A or 503B.

12 min read

GLP-1 Coupons, Discounts & Promo Codes: Verified Deals (2026)

Verified GLP-1 deals from telehealth providers, checked on each provider's own site, with the few real promo codes flagged. Also covers the Zepbound, Wegovy, Ozempic and Mounjaro savings cards ($25 copay with coverage), cash self-pay prices, and free-drug programs.

9 min read

Wegovy GoodRx, NovoCare $349, Costco $349, Sam's Club: Every GLP-1 Cash-Pay Coupon & Channel (2026)

Cash prices for GLP-1s in 2026: Wegovy $349/month at NovoCare, Zepbound $299-$449 at LillyDirect, oral Wegovy $149 at Sam's Club and Foundayo $149 at Amazon Pharmacy, plus Costco and GoodRx paths, verified in May 2026.

8 min read

TrumpRx GLP-1 Prices: Zepbound, Wegovy, Ozempic, Mounjaro and Foundayo

TrumpRx.gov lists Zepbound at $299 to $449, Wegovy pens at $199 then $349, the Wegovy pill at $149 to $299, Ozempic at $199 to $499, Mounjaro at $499 and Foundayo at $149 to $299 — every one identical to the manufacturer's own LillyDirect or NovoCare self-pay price.

11 min read

Where to get GLP-1 safely: vetted online providers

Vetted telehealth providers that prescribe online. We compare pricing, form, and states served.

No insurance needed · vetted by our editors

WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. How we make money

7.8

Embody

Low flat-rate compounded GLP-1 pricing at every dose

Read full review →

From $79/mo

sale price

Get started →
8.2

Gala

Compounded semaglutide or tirzepatide at one all-doses price on a yearly plan, with free shipping

Read full review →

From $129/mo

starting dose

Get started →
8.3

Found

Medication-included compounded GLP-1 on 28-day cash plans, plus insurance help for brand-name GLP-1s

Read full review →

From $289/4 wks

billed per 4 weeks

Get started →

About this analysis

Weight Loss Rankings is an independent editorial publication. Our provider dataset is verified directly against each provider's website and updated continuously. Read our full methodology →